LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Aandelen Lijst・SCYNEXIS Inc

SCYNEXIS Inc

Gesloten

0.8 -3.61

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.8

Max

0.83

Belangrijke statistieken
By Trading Economics
Inkomsten	21M 12M
Verkoop	18M 19M
Winstmarge	65.741
Werknemers	18
EBITDA	11M 11M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+316.67% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	7.7M 39M
Vorige openingsprijs	4.41
Vorige sluitingsprijs	0.8

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

0.9307 / 0.9907 Steun & Weerstand

SCYNEXIS Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mrt 2026, 17:33 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mrt 2026, 17:00 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mrt 2026, 16:03 UTC

Belangrijke Nieuwsgebeurtenissen

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 mrt 2026, 14:50 UTC

Belangrijke Marktbewegers

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 mrt 2026, 14:37 UTC

Acquisities, Fusies, Overnames

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 mrt 2026, 14:29 UTC

Belangrijke Nieuwsgebeurtenissen

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27 mrt 2026, 14:16 UTC

Belangrijke Nieuwsgebeurtenissen

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 19:16 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mrt 2026, 19:07 UTC

Marktinformatie

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mrt 2026, 19:04 UTC

Marktinformatie

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mrt 2026, 19:03 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 19:02 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mrt 2026, 18:12 UTC

Marktinformatie

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mrt 2026, 17:36 UTC

Belangrijke Nieuwsgebeurtenissen

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mrt 2026, 17:34 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mrt 2026, 17:29 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mrt 2026, 16:38 UTC

Marktinformatie

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mrt 2026, 16:32 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mrt 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 15:43 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 mrt 2026, 14:36 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 mrt 2026, 14:26 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27 mrt 2026, 14:14 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 14:14 UTC

Marktinformatie

Global Energy Roundup: Market Talk

Peer Vergelijking

Prijswijziging

SCYNEXIS Inc Prognose

Koersdoel

By TipRanks

316.67% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.5 USD 316.67%

Hoogste 4 USD

Laagste 3 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor SCYNEXIS Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan SCYNEXIS Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.9307 / 0.9907Steun & Weerstand

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.